Article

Potentiation of caspase-1 activation by the P2X7 receptor is dependent on TLR signals and requires NF-κB-driven protein synthesis. J Immunol

Department of Pathology, Case School of Medicine, Case Western Reserve University, Cleveland, Ohio 44106, USA.
The Journal of Immunology (Impact Factor: 5.36). 01/2006; 175(11):7611-22. DOI: 10.4049/jimmunol.175.11.7611
Source: PubMed

ABSTRACT The proinflammatory cytokines IL-1beta and IL-18 are inactive until cleaved by the enzyme caspase-1. Stimulation of the P2X7 receptor (P2X7R), an ATP-gated ion channel, triggers rapid activation of caspase-1. In this study we demonstrate that pretreatment of primary and Bac1 murine macrophages with TLR agonists is required for caspase-1 activation by P2X7R but it is not required for activation of the receptor itself. Caspase-1 activation by nigericin, a K+/H+ ionophore, similarly requires LPS priming. This priming by LPS is dependent on protein synthesis, given that cyclohexamide blocks the ability of LPS to prime macrophages for activation of caspase-1 by the P2X7R. This protein synthesis is likely mediated by NF-kappaB, as pretreatment of cells with the proteasome inhibitor MG132, or the IkappaB kinase inhibitor Bay 11-7085 before LPS stimulation blocks the ability of LPS to potentiate the activation of caspase-1 by the P2X7R. Thus, caspase-1 regulation in macrophages requires inflammatory stimuli that signal through the TLRs to up-regulate gene products required for activation of the caspase-1 processing machinery in response to K+-releasing stimuli such as ATP.

Download full-text

Full-text

Available from: George R Dubyak, Nov 02, 2014
0 Followers
 · 
125 Views
    • "Inflammasome priming normally occurs downstream of the transcription factor NF-B (Bauernfeind et al., 2009) and essentially involves trans-activation of the various genes that encode the different inflammasome subunits and their cytokine targets. Stimuli known to lead to inflammasome priming include toll-like receptor (TLR) ligands such as lipopolysaccharide (LPS), cytokines such as tumour necrosis factor (TNF), and reactive oxygen species (Bauernfeind et al., 2011; Bauernfeind et al., 2009; Kahlenberg et al., 2005). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Inflammasomes are multimeric complexes that facilitate caspase-1-mediated processing of the pro-inflammatory cytokines interleukin(IL)-1β and IL-18. Clinical hypertension is associated with renal inflammation, and elevated circulating levels of IL-1β and IL-18. Therefore, we investigated whether hypertension in mice is associated with increased expression and/or activation of the inflammasome in the kidney, and if inhibition of inflammasome activity reduces blood pressure (BP), markers of renal inflammation and fibrosis. Wild-type and inflammasome-deficient ASC(-/-) mice were uninephrectomised and received deoxycorticosterone acetate and saline to drink (1K/DOCA/salt). Control mice were uninephrectomised and received placebo and water. BP was measured by tail cuff; renal expression of inflammasome subunits and inflammatory markers was measured by real-time PCR and immunoblotting; macrophage and collagen accumulation was assessed by immunohistochemistry. 1K/DOCA/salt-induced hypertension in mice was associated with increased renal mRNA expression (fold-change vs control; P<0.05) of inflammasome subunits NLRP3 (2.3±0.2), ASC (2.8±0.6) and pro-caspase-1 (2.6±0.5), and the cytokine, pro-IL-1β (4.0±0.8), as well as protein levels of active caspase-1 (1.6±0.2) and mature IL-1β (2.1±0.3). Following treatment with 1K/DOCA/salt, ASC(-/-) mice displayed blunted pressor responses (140±3 vs 155±8 mmHg in wild-types; P<0.05), and were also protected from increases in renal expression of IL-6, IL-17A, CCL2, ICAM-1 and VCAM-1, and accumulation of macrophages and collagen. Finally, treatment with a novel inflammasome inhibitor, MCC950, reversed hypertension in 1K/DOCA/salt-treated mice. Renal inflammation, fibrosis and elevated BP induced by 1K/DOCA/salt-treatment are dependent on inflammasome activity, highlighting the inflammasome/IL-1β pathway as a potential therapeutic target in hypertension. This article is protected by copyright. All rights reserved.
    British Journal of Pharmacology 06/2015; DOI:10.1111/bph.13230 · 4.99 Impact Factor
  • Source
    • "A well-characterized route linking TLRs with the NLRP3 inflammasome is via an ATP-gated purinergic receptor, P2X 7 (Mariathasan et al., 2006) which we have previously shown to be expressed and functional in cord blood mononuclear cells (CBMCs) (Warren et al., 2008). While TLR4 leads to increased synthesis of mRNA for the precursor form of IL- 1β, processing to its mature and releasable form is reliant upon the exit of K + from cells—a role performed by the P2X 7 receptor (Kahlenberg et al., 2005). Thus, while numerous studies have shown links between TLR4 and LPS to cytokine release, stimulation with ATP increases IL-1β release further through the P2X 7 -receptor and may be a missing ingredient in understanding sPTB. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Distinguishing between fetal and maternal inflammatory responses is necessary for understanding the immune interplay either side of the placenta. Fetal immunity reaches maturity during extrauterine life and while basic inflammatory responses afford a certain degree of protection, fetuses are vulnerable to infection. With the discovery of inflammasomes-intracellular scaffolds that facilitate the elaboration of reactions resulting in the release of mature interleukin-1β (IL-1β)-it is necessary to consider how inflammatory stimuli are processed. The purinergic P2X7 receptor located on haematopoietic cells is a key intermediary in signal transduction initiated at Toll-like receptors (TLR) terminating in release of the mature IL-1β product. We demonstrate herein that IL-1β release from fetal membranes and mononuclear cells isolated from cord, placental, and maternal blood, obtained at term, is P2X7- and caspase-1 dependent. The P2X7-dependent release of the cytokine, which was highest from choriodecidua, was attenuated by progesterone (P4), prolactin and an NFkB inhibitor. The NLRP3 inflammasome appears necessary for the processing of IL-1β in gestational tissues and leukocytes.
    Frontiers in Physiology 06/2015; 6:186. DOI:10.3389/fphys.2015.00186 · 3.50 Impact Factor
  • Source
    • "The P2X7 receptor is part of the multiprotein complex called the inflammasome [66], which is central in the events during initiation of the inflammatory response in the innate immune system [34], and especially in the initiation phase macrophages, monocytes and dendritic cells are predominantly involved in the innate immune response. Here, P2X7 receptor activation induces activation of the NALP3 inflammasome leading to conversion of procaspase-1 to caspase-1 [67] [68]. Caspase-1 is involved in processing and release of IL-1 and IL-18 with subsequent systemic effects in the immune system and possibly also in bone. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Inflammatory diseases are often multiorganic diseases with manifestations not related directly to the primary affected organ. They are often complicated by a generalized bone loss that subsequently leads to osteoporosis and bone fractures. The exact mechanism for the accompanying bone loss is not understood in full detail, but factors such as glucocorticoid treatment, immobilization, malnutrition, and insufficient intake of vitamin D play a role. However, it has become evident that the inflammatory process itself is involved and the resulting bone loss is termed immune-mediated bone loss. It stems from an increase in bone resorption and the pro-inflammatory cytokines tumor necrosis factor alpha and interleukin 1 beta and has been shown to not only mediate the inflammatory response but also to strongly stimulate bone degradation. The purinergic P2X7 receptor is central in the processing of these two cytokines and in the initiation of the inflammatory response, and it is a key molecule in the regulation of both bone formation and bone resorption. The aim of this review is therefore to provide evidence-based novel hypotheses of the role of ATP-mediated purinergic signalling via the P2X7 receptor in immune-mediated bone loss and -osteoporosis.
    The Scientific World Journal 01/2014; 2014:954530. DOI:10.1155/2014/954530 · 1.73 Impact Factor
Show more